{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:32:53Z","timestamp":1786440773054,"version":"build-2736575974"},"reference-count":232,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd016104","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:57:08Z","timestamp":1783958228000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative immune checkpoint inhibitors with or without chemotherapy versus placebo with or without chemotherapy in elderly people with localised non-small cell lung cancer"],"prefix":"10.1002","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7817-2405","authenticated-orcid":false,"given":"Eva","family":"Plissonneau","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology; University Hospital of Besan\u00e7on; Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corynne","family":"Marchal","sequence":"additional","affiliation":[{"name":"Marie & Louis Pasteur University; Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Malouf","sequence":"additional","affiliation":[{"name":"Oxford Population Health; University of Oxford; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Calais","sequence":"additional","affiliation":[{"name":"Health Sciences University Library; Marie & Louis Pasteur University; Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Westeel","sequence":"additional","affiliation":[{"name":"Department of Chest Diseases and Thoracic Oncology; University Hospital of Besan\u00e7on; Besan\u00e7on France"},{"name":"EFS, INSERM, UMR RIGHT; Marie & Louis Pasteur University; Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Orillard","sequence":"additional","affiliation":[{"name":"EFS, INSERM, UMR RIGHT; Marie & Louis Pasteur University; Besan\u00e7on France"},{"name":"Department of Medical Oncology; University Hospital of Besan\u00e7on; Besan\u00e7on France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD016104-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA : A Cancer Journal for Clinicians"},{"issue":"1","key":"10.1002\/14651858.CD016104-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5334\/aogh.2419","article-title":"Global epidemiology of lung cancer","volume":"85","author":"Barta","year":"2019","journal-title":"Annals of Global Health"},{"key":"10.1002\/14651858.CD016104-BIB0003|cit3","unstructured":"Cancer stat facts \u2014 lung and bronchus cancer https:\/\/seer.cancer.gov\/statfacts\/html\/lungb.html"},{"issue":"4","key":"10.1002\/14651858.CD016104-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD016104-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0006|cit6","unstructured":"NCCN clinical practice guidelines in oncology, non-small cell lung cancer, version 8.2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"issue":"4","key":"10.1002\/14651858.CD016104-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Molecular Cancer Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD016104-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/cncr.32468","article-title":"Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC)","volume":"126","author":"Bodor","year":"2020","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD016104-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","article-title":"The evolving landscape of biomarker testing for non-small cell lung cancer in Europe","volume":"154","author":"Kerr","year":"2021","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1002\/14651858.CD016104-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"e196879","DOI":"10.1001\/jamanetworkopen.2019.6879","article-title":"Association of survival and immune-related biomarkers with immunotherapy in patients with non-small cell lung cancer: a meta-analysis and individual patient-level analysis","volume":"2","author":"Yu","year":"2019","journal-title":"JAMA Network Open"},{"issue":"4","key":"10.1002\/14651858.CD016104-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging and systemic and local therapy","volume":"28","author":"Remon","year":"2021","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD016104-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"Journal of Thoracic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD016104-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3978\/j.issn.2218-6751.2014.06.01","article-title":"Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art","volume":"4","author":"Cort\u00e9s","year":"2015","journal-title":"Translational Lung Cancer Research"},{"issue":"9928","key":"10.1002\/14651858.CD016104-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0140-6736(13)62159-5","article-title":"Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data","volume":"383","author":"Burdett","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD016104-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nature. Immunology"},{"key":"10.1002\/14651858.CD016104-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annual Review of Immunology"},{"issue":"12","key":"10.1002\/14651858.CD016104-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD016104-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1002\/14651858.CD016104-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.3389\/fimmu.2019.01719","article-title":"T cell dysfunction in cancer immunity and immunotherapy","volume":"10","author":"Xia","year":"2019","journal-title":"Frontiers in Immunology"},{"key":"10.1002\/14651858.CD016104-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"1490302","DOI":"10.3389\/fragi.2024.1490302","article-title":"The 3 I\u2019s of immunity and aging: immunosenescence, inflammaging, and immune resilience","volume":"5","author":"Wrona","year":"2024","journal-title":"Frontiers in Aging"},{"key":"10.1002\/14651858.CD016104-BIB0021|cit21","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"National Institute of Diabetes and Digestive and Kidney Diseases","year":"2022"},{"issue":"11","key":"10.1002\/14651858.CD016104-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1002\/14651858.CD016104-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"730666","DOI":"10.3389\/fimmu.2021.730666","article-title":"Toripalimab: the first domestic anti-tumor PD-1 antibody in China","volume":"12","author":"Zhang","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1002\/14651858.CD016104-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.seminoncol.2015.02.002","article-title":"PD-L1 inhibition with MPDL3280A for solid tumors","volume":"42","author":"Cha","year":"2015","journal-title":"Seminars in Oncology"},{"issue":"9","key":"10.1002\/14651858.CD016104-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunology Research"},{"issue":"6","key":"10.1002\/14651858.CD016104-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"L\u00f3pez-Ot\u00edn","year":"2013","journal-title":"Cell"},{"key":"10.1002\/14651858.CD016104-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3389\/fimmu.2019.02247","article-title":"Immunosenescence and its hallmarks: How to oppose aging strategically? A review of potential options for therapeutic intervention","volume":"10","author":"Aiello","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"10.1002\/14651858.CD016104-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3390\/ijms20112810","article-title":"The evolving role of CD8+CD28- immunosenescent T cells in cancer immunology","volume":"20","author":"Huff","year":"2019","journal-title":"International Journal of Molecular Science"},{"issue":"2","key":"10.1002\/14651858.CD016104-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/1078-0432.CCR-20-1420","article-title":"Circulating T-cell immunosenescence in patients with advanced non-small cell lung cancer treated with single-agent PD-1\/PD-L1 inhibitors or platinum-based chemotherapy","volume":"27","author":"Ferrara","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD016104-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/thoraxjnl-2014-206677","article-title":"Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group","volume":"71","author":"Dietel","year":"2016","journal-title":"Thorax"},{"issue":"11","key":"10.1002\/14651858.CD016104-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.annonc.2025.08.003","article-title":"Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Zer","year":"2025","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD016104-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41571-023-00794-7","article-title":"Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges","volume":"20","author":"Mountzios","year":"2023","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD016104-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","article-title":"Adverse events following cancer immunotherapy: obstacles and opportunities","volume":"40","author":"Pauken","year":"2019","journal-title":"Trends in Immunology"},{"issue":"8","key":"10.1002\/14651858.CD016104-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD016104-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncology"},{"issue":"8175","key":"10.1002\/14651858.CD016104-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"issue":"9","key":"10.1002\/14651858.CD016104-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD016104-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016104-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"113404","DOI":"10.1016\/j.ejca.2023.113404","article-title":"Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: impact of clinicopathological factors and indirect comparison between treatment strategies","volume":"195","author":"Nuccio","year":"2023","journal-title":"European Journal of Cancer"},{"issue":"9","key":"10.1002\/14651858.CD016104-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1002\/14651858.CD016104-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016104-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1158\/1538-7445.AM2018-1719","article-title":"Abstract 1719 Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer","volume":"Suppl 13","author":"Cascone","year":"2018","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD016104-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"S1622","DOI":"10.1016\/j.annonc.2024.10.640","article-title":"613TiP Evaluation of low dose nivolumab with neoadjuvant chemotherapy in non-small cell lung cancer: a phase II open label randomised clinical trial (ELON)","volume":"35, Suppl 4","author":"Biswal","year":"2024","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0044|cit44","unstructured":"Evaluation of low dose immunotherapy for lung cancer https:\/\/ctri.nic.in\/Clinicaltrials\/pmaindet2.php?EncHid=ODExMTE=&Enc=&userName="},{"issue":"3","key":"10.1002\/14651858.CD016104-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/JTO.0b013e31827e2145","article-title":"Elderly patients with advanced NSCLC in phase III clinical trials: are the elderly excluded from practice-changing trials in advanced NSCLC?","volume":"8","author":"Sacher","year":"2013","journal-title":"Journal of Thoracic Oncology"},{"issue":"10314","key":"10.1002\/14651858.CD016104-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","volume":"398","author":"Mohile","year":"2021","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD016104-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1093\/annonc\/mdu022","article-title":"Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology","volume":"25","author":"Pallis","year":"2014","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD016104-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41416-020-0986-4","article-title":"Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper","volume":"123","author":"Gomes","year":"2020","journal-title":"British Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD016104-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014907.pub2","article-title":"Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol","author":"Marchal","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD016104-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015495","article-title":"Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer","author":"Orillard","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD016104-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Mascaux C Greillier L Moreau L Egenod T Cadranel J First-line atezolizumab plus chemotherapy in elderly patients with advanced nsclc, IFCT-1805 elderly: a randomized, multicenter, phase 3 trial 2025 World Conference on Lung Cancer; 2025 Sep 6-9; Barcelona, Spain 2025","DOI":"10.1016\/j.jtho.2025.09.043"},{"issue":"4","key":"10.1002\/14651858.CD016104-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4103\/2229-3485.167099","article-title":"Elderly patients' participation in clinical trials","volume":"6","author":"Shenoy","year":"2015","journal-title":"Perspectives in Clinical Research"},{"key":"10.1002\/14651858.CD016104-BIB0053|cit53","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD016104-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016104-BIB0055|cit55","unstructured":"McKenzie JE Brennan SE Ryan RE Thomson HJ Johnston RV Thomas J Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016104-BIB0056|cit56","unstructured":"National Cancer Institute NCI Dictionary of Cancer Terms https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms"},{"key":"10.1002\/14651858.CD016104-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1200\/EDBK_159514","volume-title":"American Society of Clinical Oncology Educational Book","volume":"36","author":"Kluetz","year":"2016"},{"issue":"21","key":"10.1002\/14651858.CD016104-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1002\/14651858.CD016104-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD016104-BIB0060|cit60","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD016104-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD016104-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD016104-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"S1299","DOI":"10.1016\/j.annonc.2023.10.054","article-title":"LBA58 Pathological response to neoadjuvant tislelizumab (TIS) plus platinum-doublet (PtDb) chemotherapy (CT) in resectable stage II-IIIA NSCLC patients (pts) in the phase III (Ph3) RATIONALE-315 trial","volume":"34","author":"Yue","year":"2023","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0064|cit64","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Metzendorf MI Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016104-BIB0065|cit65","unstructured":"Covidence Veritas Health Innovation 2020"},{"key":"10.1002\/14651858.CD016104-BIB0066|cit66","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD016104-BIB0067|cit67","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/cochrane.org\/handbook"},{"issue":"24","key":"10.1002\/14651858.CD016104-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"8","key":"10.1002\/14651858.CD016104-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"7","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD016104-BIB0070|cit70","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/cochrane.org\/handbook"},{"issue":"7109","key":"10.1002\/14651858.CD016104-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD016104-BIB0072|cit72","unstructured":"Boutron I Page MJ Higgins JP Altman DG Lundh A Hr\u00f3bjartsson A Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD016104-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD016104-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD016104-BIB0075|cit75","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD016104-BIB0076|cit76","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (updated August 2023). Cochrane, 2023 Available from https:\/\/cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD016104-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"S1238","DOI":"10.1016\/j.annonc.2024.08.2289","article-title":"LBA48 CCTG BR.31: a global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)","volume":"35","author":"Goss","year":"2024","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0078|cit78","unstructured":"Study of adjuvant MEDI4736 in completely resected lung cancer patients https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-004946-83\/IT"},{"key":"10.1002\/14651858.CD016104-BIB0079|cit79","unstructured":"A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 In completely resected non-small cell lung cancer https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=368076&isReview=true"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD016104-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"198-9","DOI":"10.1111\/ajco.13089","article-title":"BR31: a phase 3, double blind, placebo controlled, randomised trial of adjuvant durvalumab in completely resected non-small cell lung cancer","volume":"14","author":"Mersiades","year":"2018","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD016104-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"S98-9","DOI":"10.1016\/S1556-0864(25)00330-2","article-title":"LBA3: sites of relapse and subsequent therapy in the BR.31 phase III study of durvalumab vs placebo in resected stage IB-IIIA NSCLC","volume":"20","author":"Westeel","year":"2025","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0082|cit82","unstructured":"Double blind placebo controlled study of adjuvant MEDI4736 in completely resected NSCLC https:\/\/clinicaltrials.gov\/study\/NCT02273375"},{"issue":"9","key":"10.1002\/14651858.CD016104-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"S2-3","DOI":"10.1016\/j.jtho.2022.07.014","article-title":"PL03.12 Progression free survival and overall survival in NADIM II study","volume":"17","author":"Provencio","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0084|cit84","unstructured":"NADIM II: neo-adjuvant immunotherapy (NADIMII) https:\/\/clinicaltrials.gov\/study\/NCT03838159"},{"issue":"Suppl 16","key":"10.1002\/14651858.CD016104-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"8501","DOI":"10.1200\/JCO.2022.40.16_suppl.8501","article-title":"Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial","volume":"40","author":"Provencio-Pulla","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD016104-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"S138-9","DOI":"10.1016\/S1556-0864(25)00404-6","article-title":"Prognostic value of minimal residual disease in the NADIM II trial","volume":"20","author":"Serna-Blasco","year":"2025","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0087|cit87","unstructured":"Study of chemotherapy and immunotherapy for patients with lung cancer bounded in the thorax and potentially resectable https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-004515-45\/ES"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD016104-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"6684","DOI":"10.1158\/1538-7445.AM2024-6684","article-title":"Abstract 6684: Impact of fecal microbiome on the efficacy of neoadjuvant chemo-immunotherapy and colitis adverse events: findings from the NADIM II Trial","volume":"84","author":"Serna-Blasco","year":"2024","journal-title":"Cancer Research"},{"issue":"3","key":"10.1002\/14651858.CD016104-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: The Neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD016104-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"A223-4","DOI":"10.1136\/jitc-2020-SITC2020.0366","article-title":"366 A randomized double-blind placebo-controlled phase III study evaluating perioperative toripalimab combined with platinum-based doublet chemotherapy in resectable stage III NSCLC","volume":"8","author":"Wang","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1002\/14651858.CD016104-BIB0091|cit91","unstructured":"Phase III study of toripalimab versus placebo plus chemotherapy in resectable NSCLC https:\/\/clinicaltrials.gov\/study\/NCT04158440"},{"key":"10.1002\/14651858.CD016104-BIB0092|cit92","doi-asserted-by":"crossref","unstructured":"Lu S Wu L Zhang W Zhang P Wang W Fang W Perioperative toripalimab + platinum-doublet chemotherapy versus chemotherapy in resectable stage II\/III non-small cell lung cancer (NSCLC): interim event-free survival (EFS) analysis of the phase III NEOTORCH study Journal of Clinical Oncology 2023 8501 10.1200\/jco.2023.41.16_suppl.8501","DOI":"10.1200\/JCO.2023.41.16_suppl.8501"},{"issue":"10","key":"10.1002\/14651858.CD016104-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jamaoncol.2023.2751","article-title":"Neoadjuvant camrelizumab plus platinum-based chemotherapy versus chemotherapy alone for Chinese patients with resectable stage IIIA or IIIB (T3N2) non\u2013small cell lung cancer : The TD-FOREKNOW randomized clinical trial","volume":"9","author":"Lei","year":"2023","journal-title":"JAMA Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD016104-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"100161","DOI":"10.1016\/j.iotech.2022.100161","article-title":"56O A randomized, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in resectable stage IIIA and IIIB (T3N2) non-small-cell lung cancer","volume":"16","author":"Lei","year":"2022","journal-title":"ESMO Immuno-Oncology and Technology"},{"key":"10.1002\/14651858.CD016104-BIB0095|cit95","unstructured":"Camrelizumab combined with albumin-bound paclitaxel and platinum in neoadjuvant treatment of resectable NSCLC https:\/\/clinicaltrials.gov\/study\/NCT04338620"},{"issue":"10308","key":"10.1002\/14651858.CD016104-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD016104-BIB0097|cit97","unstructured":"Study to assess safety and efficacy of atezolizumab (MPDL3280A) compared to best supportive care following chemotherapy in patients with lung cancer https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&EUCT=2023-505981-26-00 2023"},{"issue":"10","key":"10.1002\/14651858.CD016104-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","article-title":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","volume":"34","author":"Felip","year":"2023","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD016104-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jtcvs.2023.01.012","article-title":"Safety of adjuvant atezolizumab after pneumonectomy\/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial","volume":"166","author":"Lee","year":"2023","journal-title":"Journal of Thoracic and Cardiovascular Surgery"},{"key":"10.1002\/14651858.CD016104-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"S464","DOI":"10.1016\/j.annonc.2022.05.063","article-title":"PS1-5 IMpower010: results from Asian patients in a phase 3 study of adjuvant atezolizumab in resected stage IB-IIIA NSCLC","volume":"33","author":"Kenmotsu","year":"2022","journal-title":"Annals of Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD016104-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"8500","DOI":"10.1200\/JCO.2021.39.15-suppl.8500","article-title":"IMpower010: primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC)","volume":"39","author":"Wakelee","year":"2021","journal-title":"Journal of Clinical Oncology (ASCO Annual Meeting)"},{"key":"10.1002\/14651858.CD016104-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"145-6","DOI":"10.1159\/000521004","article-title":"80O Atezolizumab (atezo) versus best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study","volume":"45","author":"Felip","year":"2022","journal-title":"Annals of Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD016104-BIB0103|cit103","first-page":"TPS85","article-title":"A phase III trial to compare atezolizumab (atezo) versus best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: iMpower010","volume":"35","author":"Wakelee","year":"2017","journal-title":"Journal of Clinical Oncology (ASCO Annual Meeting)"},{"issue":"11","key":"10.1002\/14651858.CD016104-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1016\/j.jtho.2023.09.193","article-title":"MA11.08 IMpower010: Exploratory analysis of tumour mutational burden and disease-free survival with adjuvant atezolizumab in NSCLC","volume":"18","author":"Felip","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD016104-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"S1305","DOI":"10.1016\/j.jtho.2016.11.1845","article-title":"P3.02c-050 IMpower010: phase III study of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with completely resected NSCLC","volume":"12","author":"Wakelee","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0106|cit106","unstructured":"Study to assess safety and efficacy of atezolizumab (MPDL3280A) compared to best supportive care following chemotherapy in patients with lung cancer https:\/\/clinicaltrials.gov\/study\/NCT02486718"},{"key":"10.1002\/14651858.CD016104-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"S1374","DOI":"10.1016\/j.annonc.2021.10.018","article-title":"2O IMpower010: biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) versus best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC","volume":"32","author":"Zhou","year":"2021","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1002\/14651858.CD016104-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"S2398","DOI":"10.1016\/j.jtho.2017.11.017","article-title":"P2.04-004 IMpower010: a phase III study of atezolizumab versus best supportive care following adjuvant chemotherapy in completely resected NSCLC","volume":"12","author":"Felip","year":"2017","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0109|cit109","doi-asserted-by":"crossref","unstructured":"Wakelee HA Altorki N Zhou C Cs\u00f6szi T \u00a0Vynnychenko IO Goloborodko A LBA8035, Poster 297 IMpower-010: disease-free survival final analysis and second overall survival interim analysis results after >5 years of follow-up of a phase III study of adjuvant atezolizumab versus best supportive care in resected stage IB-IIIA non-small cell lung cancer European Society for Medical Oncology (ESMO) 2024 Annual Meeting; 2024 Sep 13-17; Barcelona, Spain 2024","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8035"},{"issue":"10","key":"10.1002\/14651858.CD016104-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"S845-6","DOI":"10.1016\/j.jtho.2021.08.031","article-title":"PL02.05 IMpower010: characterization of stage IB-IIIA NSCLC patients by type and extent of therapy prior to adjuvant atezolizumab","volume":"16","author":"Altorki","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1200\/JCO-24-01681","article-title":"Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non\u2013small cell lung cancer (IMpower010): an open-label, randomized, phase III trial","volume":"43","author":"Felip","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD016104-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"S779-80","DOI":"10.1016\/j.annonc.2024.08.1270","article-title":"1211P IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)","volume":"35","author":"Wakelee","year":"2024","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD016104-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"CT239","DOI":"10.1158\/1538-7445.AM2024-CT239","article-title":"IMpower010: updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC","volume":"84","author":"Wang","year":"2024","journal-title":"American Association for Cancer Research"},{"key":"10.1002\/14651858.CD016104-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"S1319","DOI":"10.1016\/j.annonc.2021.08.2120","article-title":"LBA9 IMpower010: sites of relapse and subsequent therapy from a phase III study of atezolizumab versus best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC","volume":"32","author":"Felip","year":"2021","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"ix134-5","DOI":"10.1093\/annonc\/mdw592.004","article-title":"429TiP IMpower010: a phase III trial investigating atezolizumab (atezo) versus best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC","volume":"27","author":"Zhou","year":"2016","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1002\/14651858.CD016104-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1111\/cas.15564","article-title":"Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010)","volume":"113","author":"Kenmotsu","year":"2022","journal-title":"Cancer Science"},{"issue":"9","key":"10.1002\/14651858.CD016104-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jtho.2022.07.013","article-title":"PL03.09 IMpower010: overall survival interim analysis of a phase III study of atezolizumab versus best supportive care in resected NSCLC","volume":"17","author":"Wakelee","year":"2022","journal-title":"Journal of Thoracic Oncology"},{"issue":"16","key":"10.1002\/14651858.CD016104-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"8522","DOI":"10.1200\/jco.2023.41.16_suppl.8522","article-title":"IMpower010: exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab versus best supportive care","volume":"41","author":"Reck","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0119|cit119","unstructured":"A phase III, open-label, randomized study to investigate the efficacy and safety of atezolizumab (anti-PD-L1 antibody) compared with best supportive care following lung cancer resection and chemotherapy for early-stage lung cancer https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2014-003205-15\/PT"},{"key":"10.1002\/14651858.CD016104-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"101027","DOI":"10.1016\/j.iotech.2024.101027","article-title":"LBA3 Perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) in early-stage non-small-cell lung cancer (NSCLC): a 4-year update of KEYNOTE-671","volume":"24","author":"Majem","year":"2024","journal-title":"ESMO Immuno-Oncology and Technology (ESMO Immuno-Oncology Congress)"},{"issue":"Suppl 17","key":"10.1002\/14651858.CD016104-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"LBA100","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA100","article-title":"KEYNOTE-671: randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC","volume":"41","author":"Wakelee","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"10459","key":"10.1002\/14651858.CD016104-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(24)01756-2","article-title":"Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Spicer","year":"2024","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD016104-BIB0123|cit123","unstructured":"Efficacy and safety of pembrolizumab (MK-3475) With platinum doublet chemotherapy as neoadjuvant\/adjuvant therapy for participants with resectable stage II, IIIA, and resectable IIIB (T3-4N\") non-small cell lung cancer (MK-3475-671\/KEYNOTE-671) https:\/\/clinicaltrials.gov\/study\/NCT03425643"},{"key":"10.1002\/14651858.CD016104-BIB0124|cit124","doi-asserted-by":"publisher","first-page":"S801-2","DOI":"10.1016\/j.annonc.2020.08.1437","article-title":"1235TiP Perioperative pembrolizumab + platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: the phase III KEYNOTE-671 study","volume":"31","author":"Tsuboi","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0125|cit125","doi-asserted-by":"publisher","first-page":"S778-9","DOI":"10.1016\/j.annonc.2024.08.1269","article-title":"1210P Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: subgroup analyses of the phase III KEYNOTE-671 study","volume":"35","author":"Garassino","year":"2024","journal-title":"Annals of Oncology"},{"issue":"Suppl 16","key":"10.1002\/14651858.CD016104-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/JCO.2024.42.16_suppl.8012","article-title":"Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage nonsmall-cell lung cancer (NSCLC)","volume":"42","author":"Garassino","year":"2024","journal-title":"Journal of Clinical Oncology (ASCO Annual Meeting)"},{"issue":"10","key":"10.1002\/14651858.CD016104-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.jtho.2024.09.022","article-title":"Association of pathologic regression with EFS in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage NSCLC","volume":"19","author":"Jones","year":"2024","journal-title":"Journal of Thoracic Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD016104-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"TPS8583","DOI":"10.1200\/JCO.2018.36.15-suppl.TPS8583","article-title":"Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671","volume":"36","author":"Fernando","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"S1297-8","DOI":"10.1016\/j.annonc.2023.10.052","article-title":"LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)","volume":"34","author":"Spicer","year":"2023","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0130|cit130","unstructured":"Chemo +\/- pembrolizumab (MK-3475) as perioperative therapy for resectable stage IIB or IIIA NSCLC https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2017-001832-21\/BE"},{"issue":"10","key":"10.1002\/14651858.CD016104-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O'Brien","year":"2022","journal-title":"Lancet. Oncology"},{"issue":"Suppl 16","key":"10.1002\/14651858.CD016104-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"8512","DOI":"10.1200\/JCO.2022.40.16_suppl.8512","article-title":"EORTC-1416-LCG\/ETOP 8-15 - PEARLS\/KEYNOTE-091 study of pembrolizumab versus placebo for completely resected early-stage non-small cell lung cancer (NSCLC): outcomes in subgroups related to surgery, disease burden, and adjuvant chemotherapy use","volume":"40","author":"O'Brien","year":"2022","journal-title":"Journal of Clinical Oncology (ASCO annual Meeting)"},{"key":"10.1002\/14651858.CD016104-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"S971-2","DOI":"10.1016\/j.annonc.2022.07.1056","article-title":"930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: subgroup analysis of PEARLS\/KEYNOTE-091","volume":"33","author":"Peters","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0134|cit134","unstructured":"Study of pembrolizumab (MK-3475) versus placebo for participants with non-small cell lung cancer after resection with or without standard adjuvant therapy (MK-3475-091\/KEYNOTE-091) https:\/\/clinicaltrials.gov\/study\/NCT02504372"},{"issue":"16","key":"10.1002\/14651858.CD016104-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1200\/jco.2023.41.16_suppl.8520","article-title":"Pembrolizumab versus placebo for early-stage non-small-cell lung cancer after resection and adjuvant therapy: subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS\/KEYNOTE-091 study","volume":"41","author":"Oselin","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD016104-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"451-3","DOI":"10.1016\/j.annonc.2022.02.224","article-title":"VP3-2022: pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: randomized, triple-blind, phase III EORTC-1416-LCG\/ETOP 8-15 \u2013 PEARLS\/KEYNOT","volume":"33","author":"Paz-Ares","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"100592","DOI":"10.1016\/j.iotech.2023.100592","article-title":"120MO: Adjuvant pembrolizumab versus placebo for early-stage NSCLC after resection and optional chemotherapy: updated results from PEARLS\/KEYNOTE-091","volume":"20 Suppl","author":"Besse","year":"2023","journal-title":"ESMO Immuno-Oncology and Technology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD016104-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"TPS8571","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS8571","article-title":"EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372)","volume":"34","author":"O\u2019Brien","year":"2016","journal-title":"Journal of Clinical Oncology (ASCO annual Meeting)"},{"key":"10.1002\/14651858.CD016104-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"iii23","DOI":"10.1093\/annonc\/mdx085.013","article-title":"A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (EORTC\/ETOP 1416-PEARLS)","volume":"28","author":"Paz-Ares","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0140|cit140","unstructured":"Immunotherapeutic treatment with pembrolizumab (antibody) in patients with early stage non-small cell lung cancer https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-000575-27\/SI"},{"key":"10.1002\/14651858.CD016104-BIB0141|cit141","unstructured":"A study of neoadjuvant\/adjuvant durvalumab for the treatment of patients with resectable non-small cell lung cancer https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-002997-29\/HU"},{"key":"10.1002\/14651858.CD016104-BIB0142|cit142","unstructured":"A study of neoadjuvant\/adjuvant durvalumab for the treatment of patients with resectable non-small cell lung cancer https:\/\/clinicaltrials.gov\/study\/NCT03800134"},{"issue":"10","key":"10.1002\/14651858.CD016104-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"S625","DOI":"10.1016\/j.jtho.2019.08.1318","article-title":"P1.18-02 The AEGEAN phase 3 trial of neoadjuvant\/adjuvant durvalumab in patients with resectable stage II\/III NSCLC","volume":"14","author":"Heymach","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD016104-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"e247-51","DOI":"10.1016\/j.cllc.2021.09.010","article-title":"Design and rationale for a phase III, double-blind, placebo-controlled study of neoadjuvant durvalumab\u202f+\u202fchemotherapy followed by adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small-cell lung cancer: the AEGEAN Trial","volume":"23","author":"Heymach","year":"2022","journal-title":"Clinical Lung Cancer"},{"key":"10.1002\/14651858.CD016104-BIB0145|cit145","doi-asserted-by":"crossref","unstructured":"Heymach JV Reck M Mitsudomi T Taube JM Spira A Chaft J Outcomes with perioperative durvalumab in patients with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): an exploratory subgroup analysis of AEGEAN 2024 ASCO Annual Meeting; 2024, May 31-Jun 4; Chicago (IL) 2024","DOI":"10.1200\/JCO.2024.42.16_suppl.8011"},{"issue":"11","key":"10.1002\/14651858.CD016104-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"S72-3","DOI":"10.1016\/j.jtho.2023.09.071","article-title":"OA12.06 neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in resectable EGFR-mutated NSCLC (AEGEAN)","volume":"18","author":"He","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"issue":"11","key":"10.1002\/14651858.CD016104-BIB0147|cit147","doi-asserted-by":"publisher","first-page":"S71-2","DOI":"10.1016\/j.jtho.2023.09.070","article-title":"OA12.05 surgical outcomes with neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in resectable NSCLC (AEGEAN)","volume":"18","author":"Mitsudomi","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"S1300","DOI":"10.1016\/j.annonc.2023.10.055","article-title":"LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial","volume":"34","author":"Reck","year":"2023","journal-title":"Annals of Oncology"},{"issue":"7","key":"10.1002\/14651858.CD016104-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"CT238","DOI":"10.1158\/1538-7445.AM2024-CT238","article-title":"Abstract CT 238 - Associations of ctDNA levels during neoadjuvant treatment with pathological response in patients with resectable NSCLC from the phase 3 AEGEAN trial","volume":"84","author":"Gale","year":"2024","journal-title":"Cancer Research"},{"issue":"Suppl 16","key":"10.1002\/14651858.CD016104-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1200\/JCO.2024.42.16_suppl.8011","article-title":"Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): an exploratory subgroup analysis of AEGEAN","volume":"42","author":"Heymach","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD016104-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"S38-9","DOI":"10.1016\/j.jtho.2024.09.069","article-title":"Perioperative durvalumab for resectable NSCLC (R-NSCLC): updated outcomes from the phase 3 AEGEAN trial","volume":"19","author":"Heymach","year":"2024","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"200-1","DOI":"10.1159\/000540557","article-title":"Perioperative durvalumab for resectable NSCLC: updated outcomes from the phase 3 AEGEAN trial","volume":"47","author":"Weissinger","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"25","key":"10.1002\/14651858.CD016104-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"00780","DOI":"10.1016\/j.jtho.2025.06.015","article-title":"Surgical outcomes with neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in resectable NSCLC","volume":"S1556-0864","author":"Mitsudomi","year":"2025","journal-title":"Journal of Thoracic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD016104-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"S125-6","DOI":"10.1016\/S1556-0864(25)00382-X","article-title":"Patient-reported outcomes (PROs) with perioperative durvalumab in resectable NSCLC (AEGEAN)","volume":"20","author":"Pasello","year":"2025","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"S1239","DOI":"10.1016\/j.annonc.2024.08.2290","article-title":"LBA49 Associations of ctDNA clearance (CL) during neoadjuvant Tx with pathological response and event-free survival (EFS) in pts with resectable NSCLC (R-NSCLC): expanded analyses from AEGEAN","volume":"35","author":"Reck","year":"2024","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"102702","DOI":"10.1016\/j.esmoop.2024.102702","article-title":"123P Updated safety of perioperative durvalumab for resectable NSCLC in AEGEAN","volume":"9","author":"Urban","year":"2024","journal-title":"ESMO Open"},{"key":"10.1002\/14651858.CD016104-BIB0157|cit157","doi-asserted-by":"publisher","first-page":"8-9","DOI":"10.1159\/000533576","article-title":"AEGEAN: a phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC","volume":"46","author":"Schumann","year":"2023","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD016104-BIB0158|cit158","unstructured":"A phase 3, randomized, double-blind study of chemotherapy plus nivolumab versus chemotherapy plus placebo provided before surgery, followed by nivolumab or placebo provided after surgery for participants with non-small cell lung cancer which can be completely removed by surgery https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000262-38\/IT"},{"key":"10.1002\/14651858.CD016104-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"S1295","DOI":"10.1016\/j.annonc.2023.10.050","article-title":"LBA1 CheckMate 77T: phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) versus neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II\u2013IIIb NSCLC","volume":"34","author":"Cascone","year":"2023","journal-title":"Annals of Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD016104-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"TPS9076","DOI":"10.1200\/JCO.2020.38.15-suppl.TPS9076","article-title":"Checkmate 77T: a phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC","volume":"38","author":"Cascone","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0161|cit161","unstructured":"A study of neoadjuvant chemotherapy plus nivolumab versus neoadjuvant chemotherapy plus placebo, followed by surgical removal and adjuvant treatment with nivolumab or placebo for participants with surgically removable early stage non-small cell lung cancer https:\/\/clinicaltrials.gov\/study\/NCT04025879"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD016104-BIB0162|cit162","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1055\/s-0041-1723292","article-title":"CheckMate 77 T: a phase 3 trial of neoadjuvant nivolumab (NIVO) + chemotherapy(chemo) followed by adjuvant NIVO in resectable early-stage non-small cell lung cancer (NSCLC)","volume":"75","author":"Schumann","year":"2021","journal-title":"Pneumologie"},{"key":"10.1002\/14651858.CD016104-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"102985","DOI":"10.1016\/j.esmoop.2024.102985","article-title":"LBA2 Clinical outcomes with perioperative nivolumab (NIVO) in patients (PTS) with resectable NSCLC from the phase III CheckMate 77T study","volume":"9","author":"Awad","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"10.1002\/14651858.CD016104-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"CT097","DOI":"10.1158\/1538-7445.AM2025-CT097","article-title":"Associations between percent residual viable tumor (%RVT) and efficacy with perioperative nivolumab (NIVO) for resectable NSCLC in CheckMate 77T","volume":"85","author":"Deutsch","year":"2025","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD016104-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"S1616","DOI":"10.1016\/j.annonc.2024.10.621","article-title":"Perioperative nivolumab (NIVO) in patients (pts) with resectable stage II\u2013IIIB NSCLC: checkMate 77T Chinese population analysis","volume":"35","author":"He","year":"2024","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD016104-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"S100-2","DOI":"10.1016\/S1556-0864(25)00334-X","article-title":"Outcomes by treatment (tx) cycles (cyc) with perioperative nivolumab (NIVO) in patients (pts) with resectable NSCLC from CheckMate 77 T study","volume":"20","author":"Moro-Sibilot","year":"2025","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"S1239-40","DOI":"10.1016\/j.annonc.2024.08.2291","article-title":"LBA50 Perioperative nivolumab (NIVO) versus placebo (PBO) in patients (pts) with resectable NSCLC: clinical update from the phase III CheckMate 77T study","volume":"35","author":"Provencio Pulla","year":"2024","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"102700","DOI":"10.1016\/j.esmoop.2024.102700","article-title":"Health-related quality of life (HRQoL) outcomes from CheckMate 77T: neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant NIVO in resectable NSCLC","volume":"9","author":"Spicer","year":"2024","journal-title":"ESMO Open"},{"issue":"2","key":"10.1002\/14651858.CD016104-BIB0169|cit169","doi-asserted-by":"publisher","first-page":"119-29","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet. Respiratory Medicine"},{"issue":"4","key":"10.1002\/14651858.CD016104-BIB0170|cit170","doi-asserted-by":"publisher","first-page":"S746","DOI":"10.1016\/S1556-0864(21)01936-5","article-title":"94 TiP Neoadjuvant tislelizumab or placebo + platinum-based chemotherapy followed by adjuvant tislelizumab or placebo in patients with resectable non-small cell lung cancer (NSCLC): a phase III trial in progress","volume":"16","author":"Wang","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0171|cit171","unstructured":"Comparing the efficacy and safety of a new additional treatment with tislelizumab in non-small cell lung cancer (NSCLC) https:\/\/clinicaltrials.gov\/study\/NCT04379635"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD016104-BIB0172|cit172","first-page":"S781-2","article-title":"1213P Neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS vs. neoadjuvant placebo (PBO) plus CT with adjuvant PBO in resectable non-small cell lung cancer (NSCLC): patient-reported outcomes (PRO) in the RATIONALE-315 trial","volume":"35","author":"Cappuzzo","year":"2024","journal-title":"Annals of Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD016104-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"102687","DOI":"10.1016\/j.esmoop.2024.102687","article-title":"1080 Surgical outcomes from RATIONALE-315: randomized, double-blind, phase III study of perioperative tislelizumab with neoadjuvant chemotherapy in resectable NSCLC","volume":"9","author":"Yue","year":"2024","journal-title":"ESMO Open"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD016104-BIB0174|cit174","doi-asserted-by":"publisher","first-page":"CT081","DOI":"10.1158\/1538-7445.AM2023-CT081","article-title":"Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) versus chemo in Chinese patients (pts) with resectable NSCLC in CheckMate 816","volume":"83","author":"Wang","year":"2023","journal-title":"Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD016104-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"S89-90","DOI":"10.1016\/S1556-0864(23)00338-6","article-title":"84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816","volume":"18","author":"Forde","year":"2023","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0176|cit176","doi-asserted-by":"publisher","first-page":"A1739","DOI":"10.1136\/jitc-2023-SITC2023.222-N","article-title":"LBA50 Analysis of pathological features and efficacy outcomes with neoadjuvant nivolumab (N) plus platinum-doublet chemotherapy (C) for resectable non-small cell lung cancer (NSCLC) in CheckMate 816","volume":"11","author":"Deutsch","year":"2023","journal-title":"Annals of Oncology"},{"issue":"Suppl 13","key":"10.1002\/14651858.CD016104-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"CT003","DOI":"10.1158\/1538-7445.AM2021-CT003","article-title":"Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial","volume":"81","author":"Forde","year":"2021","journal-title":"Cancer Research"},{"issue":"16","key":"10.1002\/14651858.CD016104-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"8521","DOI":"10.1200\/jco.2023.41.16_suppl.8521","article-title":"Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial","volume":"41","author":"Spicer","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0179|cit179","unstructured":"A neoadjuvant study of nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone in early stage non-small cell lung cancer (NSCLC) (CheckMate 816) https:\/\/clinicaltrials.gov\/study\/NCT02998528"},{"issue":"2","key":"10.1002\/14651858.CD016104-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cas.16030","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816","volume":"115","author":"Mitsudomi","year":"2023","journal-title":"Cancer Science"},{"key":"10.1002\/14651858.CD016104-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"S26-7","DOI":"10.1016\/S0169-5002(23)00487-7","article-title":"Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable nonsmall cell lung cancer (NSCLC) from CheckMate 816","volume":"178","author":"Spicer","year":"2023","journal-title":"Lung Cancer"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD016104-BIB0182|cit182","doi-asserted-by":"publisher","first-page":"TPS8577","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8577","article-title":"Checkmate 816: a phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC","volume":"35","author":"Forde","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD016104-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"CT012","DOI":"10.1158\/1538-7445.AM2022-CT012","article-title":"Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): event-free survival (EFS) results from the phase 3 CheckMate 816 trial","volume":"82","author":"Girard","year":"2022","journal-title":"Cancer Research (AACR Annual Meeting)"},{"key":"10.1002\/14651858.CD016104-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"S1298-9","DOI":"10.1016\/j.annonc.2023.10.053","article-title":"LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression","volume":"34","author":"Provencio Pulla","year":"2023","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0185|cit185","doi-asserted-by":"crossref","unstructured":"Spicer JD Girard N Provencio Pulla M Wang C Mitsudomi T Awad MM LBA 8010 Neoadjuvant nivolumab plus chemotherapy versus chemotherapy in patients with resectable NSCLC: 4-year update from Checkmate 816 2024 ASCO Annual Meeting; 2024; May 31-Jun 4; Chicago (IL) 2024","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8010"},{"key":"10.1002\/14651858.CD016104-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"S973-4","DOI":"10.1016\/j.annonc.2022.07.1058","article-title":"932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): health-related quality of life (HRQoL) outcomes from CheckMate 816","volume":"33","author":"Felip","year":"2022","journal-title":"Annals of Oncology"},{"issue":"12","key":"10.1002\/14651858.CD016104-BIB0187|cit187","doi-asserted-by":"publisher","first-page":"1453-62","DOI":"10.1200\/JCO-24-02239","article-title":"Neoadjuvant nivolumab plus ipilimumab versus chemotherapy in resectable lung cancer","volume":"43","author":"Awad","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD016104-BIB0188|cit188","first-page":"47","article-title":"Surgical outcomes post neoadjuvant immunotherapy in lung cancer: CheckMate 816 in Argentine subpopulation","volume":"85","author":"Damonte","year":"2025","journal-title":"Medicina"},{"key":"10.1002\/14651858.CD016104-BIB0189|cit189","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1056\/NEJMoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 17","key":"10.1002\/14651858.CD016104-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"LBA8511","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA8511","article-title":"Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): association of pathological regression with event-free survival (EFS) in CheckMate 816","volume":"40","author":"Provencio-Pulla","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"S731","DOI":"10.1016\/j.annonc.2023.09.739","article-title":"1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial","volume":"34","author":"Awad","year":"2023","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD016104-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"S831-2","DOI":"10.1016\/j.jtho.2018.08.1478","article-title":"P2.16-03 CheckMate 816: A phase 3 trial of neoadjuvant nivolumab plus ipilimumab or chemotherapy versus chemotherapy in early-stage NSCLC","volume":"13","author":"Felip","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD016104-BIB0193|cit193","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.1200\/JCO.2021.39.15-suppl.8503","article-title":"Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo alone as neoadjuvant treatment for patients with resectable non small cell lung cancer (NSCLC)","volume":"39","author":"Spicer","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0194|cit194","unstructured":"A neoadjuvant study of nivolumab and ipilimumab compared to chemotherapy doublet in early stage non-small cell lung cancer (NSCLC) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2016-003536-21\/ES"},{"key":"10.1002\/14651858.CD016104-BIB0195|cit195","unstructured":"A study evaluating the efficacy and safety of adjuvant platinum-doublet chemotherapy, with or without atezolizumab, in patients who are ctDNA positive after complete surgical resection of stage IB to select IIIB non-small cell lung cancer (CATHAYA) https:\/\/clinicaltrials.gov\/study\/NCT04611776"},{"key":"10.1002\/14651858.CD016104-BIB0196|cit196","unstructured":"Neoadjuvant PD-1 antibody plus chemotherapy in resectable stage IIIA-N2 non-small-cell lung cancer https:\/\/clinicaltrials.gov\/study\/NCT04422392"},{"issue":"3","key":"10.1002\/14651858.CD016104-BIB0197|cit197","doi-asserted-by":"publisher","first-page":"S258-9","DOI":"10.1016\/j.jtho.2021.01.376","article-title":"P03.03 MERMAID-1: a phase III study of adjuvant durvalumab plus chemotherapy in resected NSCLC patients with MRD+ post-surgery","volume":"16","author":"Peters","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD016104-BIB0198|cit198","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000518417","article-title":"MERMAID-1: a phase III study of adjuvant durvalumab plus chemotherapy in resected NSCLC patients with MRD+ post-surgery","volume":"44","author":"Reinmuth","year":"2021","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD016104-BIB0199|cit199","unstructured":"Phase III study to determine the efficacy of durvalumab in combination with chemotherapy in completely resected stage II-III non-small cell lung cancer (NSCLC) (MERMAID-1) https:\/\/clinicaltrials.gov\/study\/NCT04385368"},{"key":"10.1002\/14651858.CD016104-BIB0200|cit200","unstructured":"Phase III study to determine the efficacy of Durvalumab in combination with chemotherapy in completely resected stage II-III non-small cell lung cancer EUCTR (European Clinical Trials Registry)"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD016104-BIB0201|cit201","doi-asserted-by":"publisher","first-page":"252-3","DOI":"10.1159\/000518417","article-title":"MERMAID-2: phase 3 study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy","volume":"44","author":"Reinmuth","year":"2021","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD016104-BIB0202|cit202","unstructured":"Phase III study to evaluate the efficacy and safety of durvalumab compared to placebo in patients with NSCLC who have minimal residual disease after surgery +\/- additional therapy before or after surgery EUCTR (European Clinical Trials Registry)"},{"issue":"4","key":"10.1002\/14651858.CD016104-BIB0203|cit203","doi-asserted-by":"publisher","first-page":"S745-6","DOI":"10.1016\/S1556-0864(21)01935-3","article-title":"93 TiP MERMAID-2: phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy","volume":"16","author":"Spigel","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0204|cit204","unstructured":"Phase III study to determine efficacy of durvalumab in stage II-III non-small cell lung cancer (NSCLC) after curative intent therapy(MERMAID-2) https:\/\/clinicaltrials.gov\/study\/NCT04642469"},{"key":"10.1002\/14651858.CD016104-BIB0205|cit205","doi-asserted-by":"publisher","first-page":"108635","DOI":"10.1016\/j.lungcan.2025.108635","article-title":"ETOP 25-23 ADOPT-lung: an international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC","volume":"206","author":"Schmid","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1002\/14651858.CD016104-BIB0206|cit206","unstructured":"A study to evaluate the benefit of adding durvalumab after chemotherapy, durvalumab and surgery in patients with early-stage, operable, non-small cell lung cancer (ADOPT-lung) https:\/\/clinicaltrials.gov\/study\/NCT06284317"},{"key":"10.1002\/14651858.CD016104-BIB0207|cit207","unstructured":"Immunotherapy after surgery for people who have no remaining cancer cells after standard treatment for early-stage non-small cell lung cancer, INSIGHT trial https:\/\/clinicaltrials.gov\/study\/NCT06498635"},{"key":"10.1002\/14651858.CD016104-BIB0208|cit208","unstructured":"Efficacy of PD-1 inhibitor combination therapy in non-small cell lung cancer patients who have not achieved major pathologic response after neoadjuvant immunotherapy: a multicenter, phase II clinical trial https:\/\/clinicaltrials.gov\/study\/NCT06620822"},{"key":"10.1002\/14651858.CD016104-BIB0209|cit209","unstructured":"Efficacy of PD-1 inhibitor combination therapy in non-small cell lung cancer patients who have not achieved major pathologic response after neoadjuvant immunotherapy https:\/\/www.chictr.org.cn\/showprojEN.html?proj=247064"},{"key":"10.1002\/14651858.CD016104-BIB0210|cit210","doi-asserted-by":"publisher","first-page":"S1547","DOI":"10.1016\/j.annonc.2022.10.322","article-title":"LBA4 CANOPY-N: A phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib\u2013IIIa non-small cell lung cancer (NSCLC)","volume":"33","author":"Mok","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0211|cit211","first-page":"A4803","article-title":"Canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in patients with surgically resected non-small cell lung cancer: CANOPY-N Trial","volume":"203","author":"Lee","year":"2021","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD016104-BIB0212|cit212","unstructured":"Study of neoadjuvant and adjuvant treatment in patients with resectable non-small cell lung cancer https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-003369-37\/ES"},{"issue":"3","key":"10.1002\/14651858.CD016104-BIB0213|cit213","doi-asserted-by":"publisher","first-page":"S647-8","DOI":"10.1016\/j.jtho.2021.01.1184","article-title":"P79.05 Phase II randomized trial of neoadjuvant pembrolizumab +\/- chemotherapy for operable stage IA3-IIA non-small cell lung cancer","volume":"16","author":"Huynh","year":"2021","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0214|cit214","unstructured":"Phase-II trial of induction chemotherapy and chemoradiotherapy plus\/minus durvalumab and consolidation immunotherapy in patients with resectable stage III NSCLC (ESPADURVA) https:\/\/clinicaltrials.gov\/study\/NCT04202809"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD016104-BIB0215|cit215","doi-asserted-by":"publisher","first-page":"TPS9077","DOI":"10.1200\/JCO.2020.38.15-suppl.TPS9077","article-title":"ALCHEMIST: adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC","volume":"38","author":"Sands","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD016104-BIB0217|cit217","doi-asserted-by":"publisher","first-page":"TPS8581","DOI":"10.1200\/JCO.2018.36.15-suppl.TPS8581","article-title":"EA5142 adjuvant nivolumab in resected lung cancers (ANVIL)","volume":"36","author":"Chaft","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0218|cit218","unstructured":"Nivolumab after surgery and chemotherapy in treating patients with stage IB-IIIA non-small cell lung cancer (An ALCHEMIST treatment trial) (ANVIL) https:\/\/clinicaltrials.gov\/study\/NCT02595944"},{"key":"10.1002\/14651858.CD016104-BIB0219|cit219","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/annonc\/mdz064.014","article-title":"IMpower030: phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy","volume":"30","author":"Peters","year":"2019","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD016104-BIB0220|cit220","doi-asserted-by":"publisher","first-page":"S863","DOI":"10.1016\/j.jtho.2018.08.1553","article-title":"P2.17-27 IMpower030: phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB NSCLC with atezolizumab + chemotherapy","volume":"13","author":"Rizvi","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0221|cit221","unstructured":"A study of neoadjuvant atezolizumab plus chemotherapy versus placebo plus chemotherapy in patients with resectable stage II, IIIA, or select IIIB non-small cell lung cancer (IMpower030) https:\/\/clinicaltrials.gov\/study\/NCT03456063"},{"key":"10.1002\/14651858.CD016104-BIB0222|cit222","unstructured":"A study evaluating the efficacy and safety of neoadjuvant treatment with atezolizumab or placebo in combination with platinum-based chemotherapy in patients with resectable stage II, IIIA, or select IIIB non-small cell lung cancer EUCTR (European Clinical Trials Registry)"},{"issue":"7","key":"10.1002\/14651858.CD016104-BIB0223|cit223","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1055-9965.EPI-16-0133","article-title":"Anticipating the \"Silver Tsunami\": prevalence trajectories and comorbidity burden among older cancer survivors in the United States","volume":"25","author":"Bluethmann","year":"2016","journal-title":"Cancer Epidemiology, Biomarkers & Prevention (AACR)"},{"issue":"10","key":"10.1002\/14651858.CD016104-BIB0224|cit224","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jtho.2024.06.010","article-title":"Neoadjuvant and adjuvant treatments for early-stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer","volume":"19","author":"Spicer","year":"2024","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0225|cit225","unstructured":"European Medicines Agency (EMA) Alecensa https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/alecensa"},{"key":"10.1002\/14651858.CD016104-BIB0226|cit226","unstructured":"European Medicines Agency (EMA) Tagrisso https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tagrisso"},{"key":"10.1002\/14651858.CD016104-BIB0227|cit227","unstructured":"FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer; 18 April 2024 https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-alectinib-adjuvant-treatment-alk-positive-non-small-cell-lung-cancer"},{"key":"10.1002\/14651858.CD016104-BIB0228|cit228","unstructured":"FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with EGFR mutations; 18 December 2020 https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-adjuvant-therapy-non-small-cell-lung-cancer-egfr-mutations"},{"issue":"4","key":"10.1002\/14651858.CD016104-BIB0229|cit229","doi-asserted-by":"publisher","first-page":"e246837","DOI":"10.1001\/jamanetworkopen.2024.6837","article-title":"Neoadjuvant chemo-immunotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Banna","year":"2024","journal-title":"JAMA Network Open"},{"issue":"5","key":"10.1002\/14651858.CD016104-BIB0230|cit230","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncology"},{"key":"10.1002\/14651858.CD016104-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.07.137","article-title":"Multidisciplinary development of the Geriatric Core Dataset for clinical research in older patients with cancer: a French initiative with international survey","volume":"103","author":"Paillaud","year":"2018","journal-title":"European Journal of Cancer"},{"issue":"13","key":"10.1002\/14651858.CD016104-BIB0232|cit232","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1200\/JCO.2015.63.5839","article-title":"Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study","volume":"34","author":"Corre","year":"2016","journal-title":"Journal of Clinical Oncology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:49:53Z","timestamp":1786438193000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD016104"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":232,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd016104","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]}}}